The psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe population who cannot be adequately controlled with topical agents. The dominance of the TNF-alpha inhibitors and IL-12/23 Stelara (Janssen) is being challenged by the introduction of the highly effective IL-17 inhibitors. In particular, the uptake of Novartis’ Cosentyx has been remarkable in the first two years of its launch, but faces competition from the new IL-17 inhibitors, in particular Eli Lilly’s Taltz. In addition, Celgene’s oral PDE-4 inhibitor Otezla has been approved for over three years in the United States and is gaining steady uptake in early lines of therapy.
- · What patient share do key therapies and brands garner by line of therapy in newly diagnosed psoriasis patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed psoriasis patients?
- · How have non-TNF-alpha inhibitor biologics and Otezla been integrated into the treatment algorithm?
- · What proportion of psoriasis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- · What percentage of psoriasis patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- · What are the product-level compliance and persistency rates among drug-treated patients with psoriasis?